A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

Clinical trial NCT06909214 · RECRUITING

Trial details

NCT number: NCT06909214
Sponsor: argenx
Status: RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

New Onset Generalized Myasthenia Gravis (gMG)

Start date: 2025-04-17
Primary completion: 2026-08-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.